GeneType, a brand under Genetic Technologies, specializes in integrated genetic risk assessments for various serious health conditions, including breast, colorectal, ovarian, prostate cancers, and more. Their approach combines polygenic risk scores derived from single nucleotide polymorphisms (SNPs) with traditional clinical risk factors such as family history and demographic data. This integrated model allows for a more comprehensive understanding of an individual's risk profile, enabling healthcare providers to develop personalized preventive health plans. GeneType's assessments are designed to identify at-risk individuals who may not qualify for traditional genetic testing, thus broadening the scope of early detection and intervention strategies.

The technology behind GeneType's risk assessments is grounded in over a decade of research and development, adhering to high scientific standards. Their methods have been validated through rigorous testing against established clinical models, ensuring that the results are clinically actionable. GeneType's offerings include lifetime and short-term risk scores for various diseases, with a focus on empowering patients and providers to make informed decisions about health management. The company emphasizes the importance of early detection and personalized healthcare, aiming to transform the traditional one-size-fits-all model into a more tailored approach that considers individual genetic and clinical backgrounds.

Australia

Genetype - Unlocking personalised preventative health
Genetic Technologies (ASX: GTG, NASDAQ Global Market: GENE) is a leader in the development and commercialisation of genetic risk assessment technology.

Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.

We’re transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk.

GeneType

Company Details